Zydus Goes All-In On U.S. Oncology With 166 Million Dollar Assertio Buyout

Nikunj Parikh May 13, 2026 450 Views

Zydus Lifesciences has signed a definitive agreement to acquire U.S.-based Assertio Holdings at 23.50 dollars per share in an all-cash deal valued at approximately 166.4 million dollars. The deal instantly hands Zydus a ready-made U.S. specialty oncology commercial platform anchored by ROLVEDON, an FDA-approved oncology supportive-care biologic.

Zydus Lifesciences Limited announced on May 13, 2026, that its subsidiary Zydus Worldwide DMCC has entered into a definitive merger agreement with Assertio Holdings Inc. to acquire all outstanding shares of the Nasdaq-listed pharmaceutical company. The transaction will be executed through Zara Merger Sub Inc., a wholly owned acquisition subsidiary, via a tender offer followed by a merger.

Deal Structure And Transaction Mechanics

Under the merger agreement, Zydus will commence a tender offer within five business days to acquire all outstanding Assertio shares at 23.50 dollars per share in cash. The transaction is structured as a tender offer, followed by a second-step merger at the same price for any remaining shares not tendered, with Assertio surviving as the continuing corporation. On successful completion, Assertio will be delisted from Nasdaq, and Zydus will hold 100 percent of its outstanding shares.

Rolvedon, Platform Value And Strategic Fit

Assertio's marquee asset, ROLVEDON (eflapegrastim-xnst), is a once-per-chemotherapy-cycle, long-acting G-CSF biologic approved by the USFDA to prevent febrile neutropenia in adult cancer patients undergoing myelosuppressive chemotherapy. The product's adjusted revenue grew from 18.18 million dollars in CY2023 (only five months post-acquisition) to 60.09 million dollars in CY2024 and 68.23 million dollars in CY2025, reflecting strong commercial traction. Assertio's 170-plus community oncology accounts and established buy-and-bill infrastructure offer Zydus a ready-made base to expand a broader U.S. specialty oncology portfolio.

Regulatory Path, Advisors And Closing Timeline

The transaction is subject to customary closing conditions including the tender of a majority of Assertio's outstanding shares, regulatory approvals and shareholder compliance requirements. Zydus is advised by Paul Weiss, Rifkind, Wharton and Garrison LLP, while Moelis and Company LLC is acting as financial advisor to Assertio with Gibson, Dunn and Crutcher LLP as its legal counsel. The deal is expected to close in FY2026-27 and does not constitute a related-party transaction.

Key Highlights

Zydus to acquire all outstanding shares of Assertio at 23.50 dollars per share in cash
Total deal consideration approximately 166.4 million dollars on a fully-diluted basis
Transaction structured as tender offer followed by second-step merger
Assertio's key product ROLVEDON is FDA-approved for oncology supportive care
ROLVEDON revenue grew to 68.23 million dollars in CY2025 from 18.18 million dollars in CY2023
Assertio has 170-plus community oncology accounts and buy-and-bill infrastructure
Deal provides Zydus an immediate U.S. specialty oncology commercial footprint
Transaction expected to close in financial year 2026-27, subject to regulatory approvals
Assertio to delist from Nasdaq upon deal completion
Not a related-party transaction; no promoter or group company interest in Assertio